Drug Master Files [Member]
Finite Lived Intangible Assets By Major Class [Axis]
Patents for the AzoneTS [Member]
In-process pharmaceutical [Member]
SeriesCPreferredStock [Member]
Statement Class Of Stock [Axis]
SeriesDPreferredStock [Member]
Plan2003Member
Plan Name [Axis]
Plan2008Member
NotPursuanttoaPlanMember
Vendor 1 [Member]
Class of Warrant or Right [Axis]
Landlord [Member]
Restricted Cash and Cash Equivalents [Axis]
FDA Approval [Member]
VestingCondition [Axis]
One Year [Member]
Handok [Member]
Principal Transaction Revenue, Description of Reporting Category [Axis]
EqPlan 2003 [Member]
EqPlan 2008 [Member]
Preferred Stock
Statement, Equity Components [Axis]
Common Stock
Additional Paid-In Capital
Computer Equipment [Member]
Property, Plant and Equipment, Type [Axis]
Office and Lab Equip [Member]
Furniture and Fixtures [Member]
Manufacturing Equipment [Member]
Office and Lab Equip Max [Member]
Series B Preferred Stock [Member]
Series E Preferred Stock [Member]
Statement Class of Stock [Axis]
Equity Components [Axis]
Accumulated Deficit
Leasehold Improvements [Member]
Leasehold Improvements Max [Member]
IselinNJ [Member]
Minimum [Member]
Range [Axis]
CEO & CFO [Member]
Title of Individual [Axis]
Four Years [Member]
Derivative [Member]
Equity [Member]
Derivative [Member]
Maximum [Member]
Equity 2 [Member]
Scenario, Previously Reported [Member]
Scenario [Axis]
Restatement Adjustment [Member]
Class of Stock [Axis]
Series F Preferred Stock [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Is Entity a Well-known Seasoned Issuer?
Is Entity a Voluntary Filer?
Is Entity's Reporting Status Current?
Entity Filer Category
Entity Public Float
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement [Table]
Statement [Line Items]
ASSETS
Current Assets:
Cash and cash equivalents
Cash restricted pursuant to letters of credit
Current portion of deferred financing costs
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Other assets:
Intangible assets, net
Deferred financing costs
Other assets
Total other assets
Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
Accrued and other current liabilities
Deferred revenue from licensing arrangements, current portion
Current portion of capital lease obligation
Derivative warrant liability
Total current liabilities
Deferred revenue from licensing arrangements, net of current portion
Total liabilities
Commitments and contingencies
Stockholders' equity:
Preferred Stock, $0.01 par value; 40,000,000 shares authorized: C - 10,000 shares authorized; issued and outstanding 1,000 shares; D - 3,600,000 shares authorized; issued and outstanding 1,000,000 shares; E - 1,748,613 shares authorized, issued and outstanding; F - 5,000,000 shares authorized; issued and outstanding 840,336 shares
Common stock, $0.01 par value, authorized 150,000,000 shares, issued and outstanding 11,776,578 and 4,437,346 shares at December 31, 2013 and 2012, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity
Stockholders' Equity:
Convertible Preferred Stock: par value
Convertible Preferred Stock: authorized
Convertible Preferred Stock: outstanding
Convertible Preferred Stock: Shares Issued
Common stock, par value
Common stock, authorized
Common stock, outstanding
Common stock, Share Issued
Income Statement [Abstract]
Licensing revenues
Operating expenses:
Research and development
Selling, general and administrative
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Other income
Loss on disposals of assets
Gain on revaluation of derivative warrant liability
Other income (expense), net
Net loss before taxes
State income taxes
Net loss
Deemed dividend on beneficial conversion feature convertible preferred stock
Net loss applicable to common shareholders
Net loss per common share, basic and diluted
Basic and diluted weighted average common shares outstanding
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Share-based compensation, net
Fair value of common stock issued for services
Gain on revaluation of derivative warrant liability
Loss on disposals of assets
Amortization of discount on note payable
Amortization of deferred financing costs
Changes in assets and liabilities:
Prepaid expenses and other current assets
Deposits and other assets
Accounts payable
Deferred revenue from licensing arrangements
Accrued and other liabilities
Net cash used in operating activities
Cash Flows from Investing Activities:
Purchase of property and equipment
Decrease in restricted cash
Decrease in security deposit
Net cash provided by (used in) investing activities
Cash Flows From Financing Activities:
Repayment of credit facility
Proceeds from equity issuances
Principal payments on capital lease obligations
Capital contribution
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income taxes
Deemed dividend on beneficial conversion feature of convertible preferred stock
Conversion of convertible preferred stock into Common Stock at par value
Beginning balance, Value
Beginning balance, Shares
Proceeds from issuance of Common Stock and warrants, net, Value
Proceeds from issuance of Common Stock and warrants, net, Shares
Fair value of Common Stock issued for services, Value
Fair value of Common Stock issued for services, Shares
Proceeds from issuance of Common Stock, Series E Preferred Stock and warrants, net of cash issuance cost, Value
Proceeds from issuance of Common Stock, Series E Preferred Stock and warrants, net of cash issuance cost, Shares
Issuance of Series C and D Preferred Stock and warrants, net of cash issuance costs, Value
Issuance of Series C and D Preferred Stock and warrants, net of cash issuance costs, Shares
Issuance of Series F Preferred Stock and warrants, net of cash issuance costs, Value
Issuance of Series F Preferred Stock and warrants, net of cash issuance costs, Shares
Capital contribution
Share-based compensation, net of restricted stock cancellations, Value
Share-based compensation, net of restricted stock cancellations, Shares
Net Loss
Ending Balance
Ending Balance, Shares
Notes to Financial Statements
ORGANIZATION AND BASIS OF PRESENTATION
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY AND MANAGEMENTS' PLANS
Summary Of Significant Accounting Policies
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT
INTANGIBLE ASSETS
OPERATING LEASE COMMITMENTS
DERIVATIVE WARRANT LIABILITY
Debt Disclosure [Abstract]
EQUITY FINANCINGS
CONVERTIBLE PREFERRED STOCK
Compensation and Retirement Disclosure [Abstract]
EQUITY COMPENSATION PLAN
STOCK OPTIONS
RESTRICTED STOCK
WARRANTS
Income Taxes
INCOME TAXES
Commitments and Contingencies Disclosure [Abstract]
LITIGATION
LICENSING AND OTHER REVENUE
Accounting Changes and Error Corrections [Abstract]
REVISION OF PRIOR INTERIM PERIOD FINANCIAL STATEMENTS
Subsequent Events
SUBSEQUENT EVENTS
Summary Of Significant Accounting Policies Policies
Use of Estimates
Cash and Cash Equivalents
Intangible Assets and Other Long-Lived Assets
Property and equipment
Share-Based Payments
Fair Values of Assets and Liabilities
Derivative Instruments
Concentration of Credit Risk
Financial Instruments
Net Loss per Common Share
Segment Information
Research and Development Expenses
Income Taxes
Licensing and Other Revenue Recognition
Distinguishment of Liabilities from Equity
Recently Issued Accounting Pronouncements
Property and equipment
Intangible Assets Tables
Intangible assets
Amortization expense
Operating Lease Commitments Tables
Future minimum lease payments
Derivative Warrant Liability Tables
Derivative warrant liability
Share based compensation options
Stock Options Tables
Assumption used for stock option granted
Stock option activity
Nonvested restricted stock activity
Fair Values of Assets and Liabilities
Warrants assumptions utilized by the Company
Outstanding Warrants
Warrant Activity
Income Taxes Tables
Company's net deferred tax asset
Income taxes computed using the federal statutory income tax rate
Revision or prior interim period financial statements
Organization And Basis Of Presentation Details Narrative
Organization And Basis Of Presentation
Reverse stock split ratio
Liquidity and Management's Plans
Cash
Working capital deficit
Accumulated deficit
Net cash proceeds from MTIA Common Stock financing
Total MTIA investment
Letter of credit issued
Property and equipment, gross
Less accumulated depreciation and amortization
Property and equipment, Useful Life
Depreciation expense
Finite-Lived Intangible Assets by Major Class [Axis]
Intangible assets, carrying value
Intangible Assets Details 1
Estimated amortization expense
2015
2016
2017
2018
2019
Thereafter
Estimated amortization expense, total
Operating Lease Commitments Details
OPERATING LEASE COMMITMENTS
Year ended December, 2015
Year ended December, 2016
Year ended December, 2017
Total
Schedule of Operating Leased Assets [Table]
Operating Leased Assets [Line Items]
Facilities lease expense
Letter of credit issued
Derivative Warrant Liability Details
DERIVATIVE WARRANT LIABILITY
Derivative warrant liability
Total unrealized losses included in net loss
Total unrealized gains included in net loss
Total realized gains included in net loss
Gain on Revaluation
Derivative warrant liability
Schedule of Stock by Class [Table]
Class of Stock [Line Items]
Authorized Preferred Stock
Issued and outstanding
Par value
Shares surrendered
Redeemable value of shares surrendered
Series C stock issued as part of Series B exchange
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation
Shares Available For Issuance
Total reserved for stock options and restricted stock
Net restricted stock issued net of cancellations
Stock options granted
Add back options cancelled before exercise
Options cancelled by plan vote
Remaining shares available for future grants
Outstanding Options and Restricted Stock
Total granted
Options cancelled
Options exercised
Net shares outstanding before restricted stock
Net restricted stock issued net of cancellations
Ending Balance
Stock Options And Restricted Stock
Restricted shares of Common Stock issued
Options to purchase an aggregate of shares
Maximum authorized shares
Shares Future grants
Stock Options Details 2
Stock Options
Shares
Beginning Balance
Granted
Forfeited or expired
Ending Balance
Exercisable at June 30, 2013
Weighted-Average Exercise Price
Beginning Balance
Granted
Forfeited or expired
Ending Balance
Exercisable at June 30, 2013
Weighted-Average Remaining Contractual Term
Weighted-Average Remaining Contractual Term Outstanding
Weighted-Average Remaining Contractual Term Exercisable
Stock Options Details Narrative
Additional paid-in capital and non-cash compensation expense
Weighted-average grant-date fair value of stock options granted
Total unrecognized compensation expense
STOCK OPTIONS AND RESTRICTED STOCK
Shares
Nonvested at beginning of period
Granted
Vested
Forfeited
Nonvested at end of period
Weighted- Average Grant-DateFair Value
Nonvested at beginning of period
Granted
Vested
Forfeited
Nonvested at end of period
VestingConditionAxis [Axis]
Stock Options And Restricted Stock
Non-cash compensation expense
Outstanding restricted stock grants
Weighted average grant date value
Aggregate restricted shares of Common Stock pursuant to 2008 plan
Fair Value of restricted stock
Share-based compensation expense
Shares of non-vested restricted stock
Restricted stock to vest upon FDA approval
Total unrecognized compensation expense
Warrants Details
Risk-free interest rate
Risk-free interest rate, maximum
Expected dividend yield
Expected term (contractual term)
Expected term (contractual term), maximum
Forfeiture rate
Expected volatility
Expected volatility, maximum
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Exercise Price
Date of Expiration
Warrants outstanding
Weighted-Average remaining contractual life
Weighted average exercise price
Number exercisable
Total outstanding
Warrants Details 2
Warrants
Shares
Beginning Balance
Granted
Forfeited or expired
Ending Balance
Weighted-Average Exercise Price
Beginning Balance
Granted
Forfeited or expired
Ending Balance
Warrants Details Narrative
Fair value warrants issued
Income Taxes Details
Net operating loss carryforwards
Research credit carryforward
Acquired intangible assets, net
Restricted stock and warrants
Other temporary differences
Total deferred tax assets, net
Valuation allowance
Net deferred tax asset
Income Taxes Details 1
Income taxes benefit (expense) at statutory rate
State income tax, net of federal benefit
Permanent Differences
Gain/loss or revaluation of derivative warrant liability
Stock-based compensation expense
Other
R&D credits
Change in valuation allowance
Income taxes rate differences
Income Taxes Details Narrative
Income tax provision, state, minimum
Gross federal net operating loss carryforwards
Gross state net operating loss carryforwards
Federal research and development tax credit carryforwards
Increase in valuation allowance
Litigation Details Narrative
Mooney damages seeked in Court
Licensing and Other Revenue
Minimum licensing term
Initial licensing fee
Nonrefundable license revenue
Nonrefundable license revenue, recognizable
License revenue recognized
Licensing fee relating to Handok
Deferred revenue recognized over next twelve months
Licensing revenue
Revenues
Operating Expenses:
Total operating expenses
Loss from operations
Other Income (Expense):
Gain on disposals of assets
Gain (loss) on revaluation of derivative warrant liability
Basic and diluted weighted average common shares outstanding
Note 5. DERIVATIVE WARRANT LIABILITY
Note 5. DERIVATIVE WARRANT LIABILITY
Convertible Preferred Stock:Series D, outstanding
Convertible Preferred Stock:Series D, par value
Deemed dividend on beneficial conversion feature of Series D Convertible Preferred Stock
Deemed dividend on beneficial conversion of Series D Convertible Preferred Stock
Note 5. DERIVATIVE WARRANT LIABILITY
Document And Entity Information
EQ Plan 2003.
EQ Plan 2008.
FDAApprovalMember
Fair value of common stock and warrants issued for services
Custom Element.
Custom Element.
Custom Element.
GainLossOnRevaluationOfDerivativeWarrantLiability
Custom Element.
Custom Element.
Handok.
Initial licensing fee.
Custom Element.
Custom Element.
LandlordMember
Custom Element.
LicensingAndOtherRevenue
Minimum licensing term.
Custom Element.
Custom Element.
Custom Element.
Notes to Financial Statements
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
RestrictedStockTextBlock
ScheduleOfStockOptionActivity
Custom Element.
Custom Element.
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number1.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Shares.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
VestingConditionAxis
WarrantActivity
Warrants details outstanding.
Note 9. WARRANTS
Weighted average grant date fair value.
Weighted average exercise price.
Custom Element.
YearlyMember
Assets, Current
Assets, Noncurrent
Assets
Liabilities, Current
Liabilities
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Interest Expense
Nonoperating Income (Expense)
Net Income (Loss) Available to Common Stockholders, Basic
GainLossOnRevaluationOfDerivativeWarrantLiability
Gain (Loss) on Disposition of Assets
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Machinery and Equipment
Increase (Decrease) in Restricted Cash
Net Cash Provided by (Used in) Investing Activities
Repayments of Debt
Repayments of Long-term Capital Lease Obligations
Net Cash Provided by (Used in) Financing Activities
Shares, Issued
CapitalContribution
Income Tax, Policy [Policy Text Block]
Property, Plant and Equipment [Table Text Block]
Schedule of Derivative Liabilities at Fair Value [Table Text Block]
WarrantsTableTextBlockAbstract
Development Stage Enterprise, Deficit Accumulated During Development Stage
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Operating Leases, Future Minimum Payments, Due in Rolling Year Two
Operating Leases, Future Minimum Payments, Due in Rolling Year Three
Proceeds from Lines of Credit
Derivative Liability [Abstract]
Derivative Liability, Fair Value, Gross Liability
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
DisclosureOfCompensationRelatedCostsSharebasedPayments2Abstract
TotalUnrecognizedCompensationExpense1
SharesDetails
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber1
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted1
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAbstract
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1
BasicAndDilutedWeightedAverageCommonSharesOutstanding